Michael Schlander

2.8k total citations
121 papers, 1.7k citations indexed

About

Michael Schlander is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michael Schlander has authored 121 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Economics and Econometrics, 27 papers in Psychiatry and Mental health and 24 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michael Schlander's work include Health Systems, Economic Evaluations, Quality of Life (64 papers), Attention Deficit Hyperactivity Disorder (27 papers) and Pharmaceutical Economics and Policy (25 papers). Michael Schlander is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (64 papers), Attention Deficit Hyperactivity Disorder (27 papers) and Pharmaceutical Economics and Policy (25 papers). Michael Schlander collaborates with scholars based in Germany, United Kingdom and United States. Michael Schlander's co-authors include Chih‐Yuan Cheng, Oliver Schwarz, K. Hernández-Villafuerte, Michaël Baumann, Jorge Mestre-Ferrándiz, Diego Hernández, Jasper Ubels, Jeff Richardson, Michael Beck and Afschin Gandjour and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Psychiatry.

In The Last Decade

Michael Schlander

116 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Schlander Germany 21 534 329 296 289 218 121 1.7k
Nigel S. B. Rawson Canada 22 322 0.6× 202 0.6× 331 1.1× 123 0.4× 153 0.7× 85 2.0k
Clayton W. Schupp United States 26 304 0.6× 334 1.0× 388 1.3× 382 1.3× 140 0.6× 38 3.0k
Giulia Cavrini Italy 17 391 0.7× 138 0.4× 139 0.5× 249 0.9× 269 1.2× 41 1.8k
Rebecca Warburton Canada 19 185 0.3× 650 2.0× 153 0.5× 337 1.2× 80 0.4× 72 1.7k
Rosa Parisi United Kingdom 18 316 0.6× 239 0.7× 257 0.9× 223 0.8× 156 0.7× 56 4.0k
Juliana Pakes United States 18 266 0.5× 140 0.4× 188 0.6× 155 0.5× 180 0.8× 26 1.8k
Priscilla Velentgas United States 18 188 0.4× 149 0.5× 275 0.9× 227 0.8× 124 0.6× 42 1.8k
Steven B. Zeliadt United States 29 362 0.7× 107 0.3× 824 2.8× 105 0.4× 110 0.5× 129 2.6k
Marion McAllister United Kingdom 25 221 0.4× 74 0.2× 101 0.3× 225 0.8× 453 2.1× 50 2.0k
Paweł Kawalec Poland 24 458 0.9× 65 0.2× 160 0.5× 125 0.4× 112 0.5× 114 1.8k

Countries citing papers authored by Michael Schlander

Since Specialization
Citations

This map shows the geographic impact of Michael Schlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schlander more than expected).

Fields of papers citing papers by Michael Schlander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schlander. The network helps show where Michael Schlander may publish in the future.

Co-authorship network of co-authors of Michael Schlander

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schlander. A scholar is included among the top collaborators of Michael Schlander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schlander. Michael Schlander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lubbers, Tim, Johanna Mattson, Didier Mayeur, et al.. (2025). Financial toxicity and socioeconomic impact of cancer in Europe. ESMO Open. 10(6). 105293–105293. 1 indexed citations
2.
Cheng, Chih‐Yuan, et al.. (2024). Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis. Frontiers in Public Health. 12. 2 indexed citations
3.
Hernández, Diego, et al.. (2023). Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach. Frontiers in Public Health. 10. 946544–946544. 5 indexed citations
4.
Schneider, Jana, et al.. (2022). Out-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: a multi-regional population-based study. Journal of Cancer Survivorship. 17(6). 1639–1659. 4 indexed citations
5.
Hernández, Diego, et al.. (2022). Economic Burden of Pancreatic Cancer in Europe: a Literature Review. Journal of Gastrointestinal Cancer. 54(2). 391–407. 9 indexed citations
6.
Schlander, Michael, K. Hernández-Villafuerte, Chih‐Yuan Cheng, Jorge Mestre-Ferrándiz, & Michaël Baumann. (2021). How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics. 39(11). 1243–1269. 176 indexed citations
7.
Thong, Melissa S. Y., Daniela Doege, Lena Koch‐Gallenkamp, et al.. (2021). Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study. Journal of Cancer Research and Clinical Oncology. 148(1). 155–162. 2 indexed citations
8.
Hernández, Diego, et al.. (2021). Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?. Journal of Comparative Effectiveness Research. 10(16). 1187–1195. 10 indexed citations
9.
Hernández, Diego & Michael Schlander. (2021). Income loss after a cancer diagnosis in Germany: An analysis based on the socio‐economic panel survey. Cancer Medicine. 10(11). 3726–3740. 16 indexed citations
10.
Schlander, Michael, et al.. (2018). New Estimates of the Willingness-to-Pay for a Statistical Life Year: A Systematic Review of the Empirical Economic Literature. Value in Health. 21. S111–S111. 8 indexed citations
11.
12.
Schlander, Michael, Silvio Garattini, Søren Holm, et al.. (2014). Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. Journal of Comparative Effectiveness Research. 3(4). 399–422. 47 indexed citations
13.
14.
Schlander, Michael, Oliver Schwarz, Aribert Rothenberger, & Veit Roessner. (2010). Tic disorders: Administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample. European Psychiatry. 26(6). 370–374. 63 indexed citations
15.
Schlander, Michael. (2008). Has NICE got it right?. Current Medical Research and Opinion. 24(4). 951–966. 2 indexed citations
16.
17.
18.
Schlander, Michael. (2007). Long-acting medications for the hyperkinetic disorders. European Child & Adolescent Psychiatry. 16(7). 421–429. 8 indexed citations
19.
Schlander, Michael. (2005). [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG].. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 100(6). 314. 1 indexed citations
20.
Stadler, Michaela, et al.. (2004). A cost-utility and cost-effectiveness analysis of an acute pain service. Journal of Clinical Anesthesia. 16(3). 159–167. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nigel S. B. Rawson Breakdown of academic impact, for papers by Clayton W. Schupp Breakdown of academic impact, for papers by Giulia Cavrini Breakdown of academic impact, for papers by Rebecca Warburton Breakdown of academic impact, for papers by Rosa Parisi Breakdown of academic impact, for papers by Juliana Pakes Breakdown of academic impact, for papers by Priscilla Velentgas Breakdown of academic impact, for papers by Steven B. Zeliadt Breakdown of academic impact, for papers by Marion McAllister Breakdown of academic impact, for papers by Paweł Kawalec
Rankless by CCL
2026